Stock Events

Multicell Technologies 

$0
6
-$0-99% Tuesday 19:20

Statistics

Day High
0
Day Low
0
52W High
0
52W Low
0
Volume
500,000
Avg. Volume
0
Mkt Cap
500,099
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

1FebExpected
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
0
0.33
0.67
1
Expected EPS
0
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MCET. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap83.12B
Gilead Sciences is a biopharmaceutical company that competes in the development of therapies for life-threatening diseases, similar to Multicell's focus on novel therapeutics.
AMGEN
AMGN
Mkt Cap144.25B
Amgen is a biotech firm focusing on human therapeutics, competing in areas that overlap with Multicell's research in regenerative medicine and drug development.
Biogen
BIIB
Mkt Cap28.26B
Biogen is involved in the discovery, development, and delivery of therapies for neurological and neurodegenerative diseases, competing with Multicell's work on complex diseases.
Regeneron Pharmaceuticals
REGN
Mkt Cap96.81B
Regeneron Pharmaceuticals focuses on developing medicines for serious medical conditions, directly competing with Multicell's approach to innovative therapeutic solutions.
Vertex Pharmaceuticals
VRTX
Mkt Cap101.91B
Vertex Pharmaceuticals is known for creating novel drugs to treat serious diseases, including genetic disorders, competing with Multicell's focus on groundbreaking treatments.
Alnylam Pharmaceuticals
ALNY
Mkt Cap18.19B
Alnylam Pharmaceuticals works on RNAi therapeutics, a novel approach to medicine that competes with Multicell's innovative strategies for treating diseases.
Bluebird bio
BLUE
Mkt Cap111.52M
bluebird bio focuses on gene therapies for severe genetic diseases and cancer, competing with Multicell's work on cellular and genetic therapies.
CRISPR Therapeutics
CRSP
Mkt Cap4.67B
CRISPR Therapeutics is at the forefront of developing gene-based treatments, directly competing with Multicell's focus on innovative cellular therapies.
Novartis
NVS
Mkt Cap206.64B
Novartis is a global healthcare company that develops treatments for a wide range of diseases, competing with Multicell's broad approach to novel therapeutics.

About

Biotechnology
Health Technology
Manufacturing
Pharmaceutical Preparation Manufacturing
MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers. The company also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications. MultiCell Technologies, Inc. has a license agreement with Corning Incorporated and Pfizer Inc. The company was formerly known as Exten Industries, Inc. and changed its name to MultiCell Technologies, Inc. in April 2004. MultiCell Technologies, Inc. was founded in 1962 and is headquartered in Woonsocket, Rhode Island.
Show more...
CEO
Employees
2
Country
US
ISIN
US62544S2005

Listings